COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,254 Articles (22,733 medRxiv, 8,521 bioRxiv)

Most recent first Previous |  Page 1281: Articles 12801-12810  | Next

Evaluation of GENECUBE(R) HQ SARS-CoV-2 for anterior nasal samples and saliva samples with a new rapid examination protocol
Naito, A., Kiyasu, Y., Akashi, Y., Sugiyama, A., Michibuchi, M., Takeuchi, Y., Notake, S., Nakamura, K., Ishikawa, H., Suzuki, H.
10.1101/2021.08.23.21262454 — Posted: 2021-08-26 Discussion: Onsite
COMORBIDITY ANALYSIS: OVERLAPPING SEMICIRCLES WITH WIGNER LAW AND RANDOM MATRIX THEORY
Nolasco, O., QuezadaTellez, L. A., Salazar Flores, Y., Diaz Hernandez, A.
10.1101/2021.08.23.21262184 — Posted: 2021-08-26
An Intranasal OMV-based vaccine induces high mucosal and systemic protecting immunity against a SARS-CoV-2 infection
van der Ley, P. A., Zariri, A., van Riet, E., Oosterhoff, D., Kruiswijk, C. P.
10.1101/2021.08.25.457644 — Posted: 2021-08-26
Enhanced neutrophil extracellular trap formation in COVID-19 is inhibited by the PKC inhibitor ruboxistaurin.
Dowey, R., Cole, J., Thompson, A. A. R., Huang, C., Whatmore, J., Iqbal, A., Bradley, K. L., McKenzie, J., Hull, R. C., Lawrie, A., Condliffe, A. M., Kiss-Toth, E., Sabroe, I., Prince, L. R.
10.1101/2021.08.24.21262336 — Posted: 2021-08-26
Impact of the early stages of the COVID-19 pandemic on coverage of RMNH interventions in Ethiopia
Carter, E. D., Zimmerman, L., Qian, E., Roberton, T., Seme, A., Shiferaw, S.
10.1101/2021.08.24.21262554 — Posted: 2021-08-26
The efficacy and safety of bamlanivimab treatment against COVID-19: A meta-analysis
Xiang, H., He, B., Li, Y., Cheng, X., Zhang, Q., Peng, W.
10.1101/2021.08.24.21262580 — Posted: 2021-08-26
The Lambda variant of SARS-CoV-2 has a better chance than the Delta variant to escape vaccines
Liu, H., Wei, P., Zhang, Q., Aviszus, K., Linderberger, J., Yang, J., Liu, J., Chen, Z., Waheed, H., Reynoso, L., Downey, G., Frankel, S., Kappler, J., Marrack, P., Zhang, G.
10.1101/2021.08.25.457692 — Posted: 2021-08-26
Structural Analysis of Receptor Binding Domain Mutations in SARS-CoV-2 Variants of Concern that Modulate ACE2 and Antibody Binding
Mannar, D., Saville, J. W., Zhu, X., Srivastava, S. S., Berezuk, A. M., Zhou, S., Tuttle, K., Kim, A., Li, W., Dimitrov, D. S., Subramaniam, S.
10.1101/2021.08.25.457711 — Posted: 2021-08-26
Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains
Ying, B., Whitener, B., VanBlargan, L. A., Hassan, A. O., Shrihari, S., Liang, C.-Y., Karl, C. E., Mackin, S., Chen, R. E., Kafai, N. M., Wilks, S. H., Smith, D. J., Carreno, J. M., Singh, G., Krammer, F., Carfi, A., Elbashir, S., Edwards, D. K., Thackray, L. B., Diamond, M. S.
10.1101/2021.08.25.457693 — Posted: 2021-08-26
Durability of antibody responses elicited by a single dose of Ad26.COV2.S and substantial increase following late boosting
Sadoff, J., Le Gars, M., Cardenas, V., Shukarev, G., Vaissiere, N., Heerwegh, D., Truyers, C., de Groot, A. M., Scheper, G., Hendriks, J., Ruiz-Guinazu, J., Struyf, F., Van Hoof, J., Douoguih, M., Schuitemaker, H.
10.1101/2021.08.25.21262569 — Posted: 2021-08-26

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).